Elevance Health, Inc. (ELV)
NYSE: ELV · Real-Time Price · USD
309.81
-0.22 (-0.07%)
At close: Aug 27, 2025, 4:00 PM
310.00
+0.19 (0.06%)
After-hours: Aug 27, 2025, 6:35 PM EDT
Elevance Health Stock Forecast
Stock Price Forecast
The 14 analysts that cover Elevance Health stock have a consensus rating of "Buy" and an average price target of $411.86, which forecasts a 32.94% increase in the stock price over the next year. The lowest target is $297 and the highest is $615.
Price Target: $411.86 (+32.94%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Elevance Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Buy | 9 | 8 | 8 | 7 | 8 | 8 |
| Hold | 1 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $400 → $330 | Buy | Maintains | $400 → $330 | +6.52% | Aug 15, 2025 |
| Baird | Baird | Hold Maintains $492 → $297 | Hold | Maintains | $492 → $297 | -4.13% | Jul 25, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $472 → $384 | Buy | Maintains | $472 → $384 | +23.95% | Jul 22, 2025 |
| Barclays | Barclays | Buy Maintains $358 → $327 | Buy | Maintains | $358 → $327 | +5.55% | Jul 22, 2025 |
| Argus Research | Argus Research | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 21, 2025 |
Financial Forecast
Revenue This Year
198.78B
from 176.81B
Increased by 12.43%
Revenue Next Year
209.82B
from 198.78B
Increased by 5.55%
EPS This Year
30.19
from 25.68
Increased by 17.58%
EPS Next Year
31.86
from 30.19
Increased by 5.50%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 209.0B | 224.5B | ||
| Avg | 198.8B | 209.8B | ||
| Low | 191.1B | 196.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 18.2% | 13.0% | ||
| Avg | 12.4% | 5.6% | ||
| Low | 8.1% | -1.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 31.84 | 36.03 | |||
| Avg | 30.19 | 31.86 | |||
| Low | 28.19 | 26.43 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 24.0% | 19.3% | |||
| Avg | 17.6% | 5.5% | |||
| Low | 9.8% | -12.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.